Evotec SE (XSWX:EVT) Accounts Payable: CHF50.0 Mil (As of Mar. 2026)


XSWX:EVT Evotec SE XSWX:EVT
68 GF Score
Price CHF4.50
GF Value CHF6.99
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Evotec SE Accounts Payable?

Evotec SE XSWX:EVT +4.02% 68 Accounts Payable is CHF50.0 Mil as of Mar. 2026. GuruFocus rates XSWX:EVT with a GF Score™ of 68/100 and a GF Value™ of CHF6.99 (Possible Value Trap). The stock has 5 warning signs investors should review.

Evotec SE's Accounts Payable for the quarter that ended in Mar. 2026 was CHF50.0 Mil.

Evotec SE's quarterly Accounts Payable increased from Sep. 2025 (CHF46.2 Mil) to Dec. 2025 (CHF60.4 Mil) but then declined from Dec. 2025 (CHF60.4 Mil) to Mar. 2026 (CHF50.0 Mil).

Evotec SE's annual Accounts Payable declined from Dec. 2023 (CHF126.7 Mil) to Dec. 2024 (CHF80.1 Mil) and declined from Dec. 2024 (CHF80.1 Mil) to Dec. 2025 (CHF60.4 Mil).

Evotec SE Accounts Payable Historical Data

* Premium members only.

The historical data trend for Evotec SE's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE Accounts Payable Chart

Evotec SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75.55 96.00 126.67 80.10 60.43

Evotec SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.56 54.39 46.24 60.43 49.97
XSWX:EVT
68GF Score
Evotec SE XSWX:EVT
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evotec SE Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of CHF50.0 Mil mean?
Evotec SE (XSWX:EVT) has a Accounts Payable of CHF50.0 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Evotec SE and its competitors.
Is Evotec SE's Accounts Payable too high?
Evotec SE's current Accounts Payable is CHF50.0 Mil. Overall, Evotec SE has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Accounts Payable compare to ZTS and UTHR?
Evotec SE's Accounts Payable of CHF50.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Evotec SE and its competitors. Evotec SE's current Accounts Payable is CHF50.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (XSWX:EVT) is currently considered Possible Value Trap. The stock's GF Value™ is CHF6.99, compared to a current price of CHF4.50 — trading 35.6% below its estimated fair value. The current Accounts Payable is CHF50.0 Mil. Evotec SE's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current Accounts Payable is CHF50.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evotec SE (XSWX:EVT) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of CHF4.50 is trading 35.6% below its estimated GF Value™ of CHF6.99. GuruFocus considers Evotec SE to be Possible Value Trap.

Key valuation signals for XSWX:EVT:

  • Accounts Payable: CHF50.0 Mil
  • GF Value™: CHF6.99 vs. price of CHF4.50 (35.6% below fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
68GF Score

Get the complete analysis for XSWX:EVT

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF4.50
Price
CHF6.99
GF Value